New Journal of Chemistry
January 1, 2018
Bronislav Jurásek, František Králík, Silvie Rimpelová et al.
15 citations
The dissociative drug deschloroketamine was synthesized, and the absolute configuration of its enantiomers was determined. The in vitro cytotoxicity of each enantiomer was tested across nine different cell lines, providing data on their relative toxicities.
Drug Testing and Analysis
October 31, 2019
Kateřina Hájková, Bronislav Jurásek, Jan Čejka et al.
12 citations
Deschloroketamine, a ketamine analog sold illicitly since 2015 and sometimes misrepresented as ketamine, has potential antidepressant properties. A metabolomics study used liquid chromatography–high-resolution mass spectrometry and a validated multiple reaction monitoring method to track its metabolites in urine, serum, and brain tissue. Key metabolites—trans-dihydrodeschloroketamine, cis- and trans-dihydronordeschloroketamine, and nordeschloroketamine—were synthesized and used as standards. In serum, nordeschloroketamine and deschloroketamine concentrations ranged from 0.5 to 860 ng/mL; in brain tissue, they ranged from 0.5 to 4700 ng/g. The quantification methods showed intra-day accuracy of 80–125% and precision averaging 3–7%.
International Journal of Molecular Sciences
February 14, 2022
Bronislav Jurásek, Silvie Rimpelová, Martin Babor et al.
7 citations
A sample of the dissociative anesthetic methoxphenidine from the black market contained an unusual bromo- and chloro-zincate anion impurity. In vitro cytotoxicity tests on kidney, liver, and bladder cell lines showed that the street sample was markedly more toxic than a pure methoxphenidine standard, suggesting the impurity caused the increased toxicity. A method using X-ray powder diffraction (XRPD) was developed to identify such anions and distinguish different crystalline forms of methoxphenidine, providing additional data not captured by routine analysis.
New Journal of Chemistry
January 1, 2023
Bronislav Jurásek, Patrik Fagan, Bohumil Dolenský et al.
6 citations
Methoxphenidine, a dissociative anesthetic related to phencyclidine, was originally patented for its potential to treat neurotoxic injury. The abstract indicates that the compound was developed with therapeutic applications in mind, specifically for addressing damage to the nervous system. No further details about its efficacy, mechanism, or clinical use are provided in this text.